results at 6 months demonstrated stable


results at 6 selleck chem months demonstrated stable cardiac allograft function (mean left ventricular ejection fraction of 65 ± 3.7%) and normal LV size and LV mass (LV end-diastolic diameter 4.2 ± 0.32 cm and LV mass 147.7 ± 24.9 g). Congo Red Staining at 6 months showed only minimal amyloid recurrence in 1 patient. Table 2 Patient characteristics at time of Evaluation for OHT. Table 3 Heart transplantation results in 9 patients with cardiac amyloidosis. Age^ at time of heart transplantation; NA* (received ASCT 1 year prior to heart-kidney transplant); IABP# (left axillary artery IABP support); NA**(died within 30 days post-OHT). Four of the nine Inhibitors,research,lifescience,medical patients who received OHT have received ASCT (one underwent ASCT at a different institution and three underwent ASCT 1 year after heart transplant at our institution), with a median time between OHT and ASCT of 14 months. For these three patients, plasma-cell targeted therapy between OHT and ASCT was with lenalidomide and dexamethasone in two patients and bortezomib (Velcade) Inhibitors,research,lifescience,medical and dexamethasone in the third patient. Bortezomib was approved by the Food and Drug Administration in May 2003 for patients with multiple myeloma who had recurrence of disease after

other treatments and has been used in patients with amyloidosis.29 All three patients Inhibitors,research,lifescience,medical post-OHT followed by ASCT at our institution have done well — with 100% survival and resolution of clinical heart failure based on 23 to 39 months of available post-OHT follow-up. Inhibitors,research,lifescience,medical ASCT resulted in complete hematologic remission of the underlying amyloid process in 1 of the 3 patients (patient 2, Table 3) and partial remission in the remaining two patients. There has been no evidence of amyloid recurrence in the cardiac allograft in these three patients based on endomyocardial biopsy surveillance. One patient with partial remission post-ASCT received a donor-related kidney transplant 20 months after Inhibitors,research,lifescience,medical ASCT and is currently doing well. Discussion Cardiac amyloidosis is a potentially

life-threatening condition that describes clinically significant involvement of the heart by amyloid deposition, which in the setting of AL amyloidosis is often associated with involvement Carfilzomib of other organs. A combination of noninvasive screening tests (i.e., low-voltage ECG) and typical echocardiographic findings (i.e., left ventricular hypertrophy with biatrial enlargement in the absence of systemic hypertension) is highly suggestive of cardiac amyloidosis. CMR with LGE is a relatively new technique that detects extracellular myocyte expansion from cardiac amyloid deposition and can potentially Imatinib Mesylate manufacturer facilitate early detection of this disease. Moreover, the presence of CMR-related LGE and pattern of LGE is strongly associated with clinical and functional markers of prognosis.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>